Join
Live feed
·
PRReleasevia Quantisnow
Milestone Pharmaceuticals Inc. logo

Milestone Pharmaceuticals Announces FDA Acceptance of the Company's Response to the CRL for CARDAMYST™ (etripamil) Nasal Spray

ByQuantisnow·Wall Street's wire, on your screen.
MIST· Milestone Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MIST (Milestone Pharmaceuticals Inc.) and more on Quantisnow.